CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL - Test2 - elhamkhani - TriplyDB

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

http://www.wikidata.org/entity/Q62035110

about

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

http://www.wikidata.org/entity/Q62035110

description

clinical trial

@en

klinisch onderzoek

@nl

name

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

@en

type

label

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

@en

prefLabel

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

@en

P1050

Q62035110-C7BB01D4-C1D8-400D-90C1-BFFA1FDA7CC1

P1132

Q62035110-62CFB8FD-461B-4AD7-A650-2A541ACEFDEC

P1476

Q62035110-28518A3C-DD80-4041-9DEF-3E256372622B

P17

Q62035110-F164B61F-420D-4151-A08D-DC136601372A

P2899

Q62035110-23D23159-A6DF-4248-82A0-83DD78056961

P3098

Q62035110-9CD21E83-6D01-42F1-A8C2-1A7869500D4A

P31

Q62035110-89EAD315-D38D-4FDA-9CA7-D6A85C3C11B4

P4844

Q62035110-EEC706E3-D012-44CA-B898-D95445BA0DE8

P580

Q62035110-ABD941C7-0BF7-4180-8BBA-79C2D9503F1D

P582

Q62035110-953FF89E-9E7B-4BA0-8692-8D8F81949648

P6099

Q62035110-3F3011E7-99B0-40AF-8CA5-14388E5B1D73

P8005

Q62035110-2F46A374-1F45-444F-A68F-3DFD985C4373

P1050

P1132

25

http://www.w3.org/2001/XMLSchema#decimal

P1476

A Phase I Combination Study of ...... nic Lymphocytic Leukemia (CLL)

@en

P17

Ameeriga Ütisriigiq

P2899

18

http://www.w3.org/2001/XMLSchema#decimal

P3098

NCT03739554

http://www.w3.org/2001/XMLSchema#string

P31

P4844

P580

2019-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P582

2020-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6099

phase I clinical trial

P8005